Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Amphetamine use is associated with dysphoric states, including heightened anxiety, that emerge within 24. h of withdrawal from the drug. Corticotropin-releasing factor increases serotonin release in the central nucleus of the amygdala, and this neurochemical circuitry may play a role in mediating fear and anxiety states. We have previously shown that chronic amphetamine treatment increases corticotropin-releasing factor receptor type-2 levels in the serotonergic dorsal raphe nucleus of the rat. Therefore, we hypothesized that chronic amphetamine treatment would enhance the amygdalar serotonergic response to corticotropin-releasing factor infused into the dorsal raphe nucleus. Male rats were injected once-daily with d-amphetamine (2.5. mg/kg i.p., or saline) for two weeks. Serotonin release within the central nucleus of the amygdala in response to intra-raphe infusion of corticotropin-releasing factor (100. ng) was measured 24. h after the last treatment in urethane-anesthetized (1.8. mg/kg, i.p.) rats using in vivo microdialysis. Rats pretreated with amphetamine showed significantly enhanced serotonin release in the central nucleus of the amygdala in response to corticotropin-releasing factor infusion when compared to saline pretreated rats. Furthermore, this enhanced response was blocked by the corticotropin-releasing factor type-2 receptor antagonist antisauvagine-30 (2μg) infused into the dorsal raphe nucleus. These results suggest increased sensitivity to corticotropin-releasing factor as mediated by type-2 receptors following chronic amphetamine treatment, which may underlie dysphoric states observed during amphetamine withdrawal.

Original languageEnglish (US)
Pages (from-to)80-87
Number of pages8
JournalEuropean Journal of Pharmacology
Volume644
Issue number1-3
DOIs
StatePublished - Oct 1 2010

Fingerprint

Corticotropin-Releasing Hormone
Amphetamine
Amygdala
Serotonin
Anxiety
Dextroamphetamine
Urethane
Microdialysis
Fear
Pharmaceutical Preparations
Dorsal Raphe Nucleus
Central Amygdaloid Nucleus

Keywords

  • (Rat)
  • CRF receptor
  • Central nucleus of the amygdala
  • Dorsal raphe nucleus
  • Microdialysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala. / Scholl, Jamie L; Vuong, Shawn M.; Forster, Gina L.

In: European Journal of Pharmacology, Vol. 644, No. 1-3, 01.10.2010, p. 80-87.

Research output: Contribution to journalArticle

@article{bd090443ce2d424e8f8c28348a0d7595,
title = "Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala",
abstract = "Amphetamine use is associated with dysphoric states, including heightened anxiety, that emerge within 24. h of withdrawal from the drug. Corticotropin-releasing factor increases serotonin release in the central nucleus of the amygdala, and this neurochemical circuitry may play a role in mediating fear and anxiety states. We have previously shown that chronic amphetamine treatment increases corticotropin-releasing factor receptor type-2 levels in the serotonergic dorsal raphe nucleus of the rat. Therefore, we hypothesized that chronic amphetamine treatment would enhance the amygdalar serotonergic response to corticotropin-releasing factor infused into the dorsal raphe nucleus. Male rats were injected once-daily with d-amphetamine (2.5. mg/kg i.p., or saline) for two weeks. Serotonin release within the central nucleus of the amygdala in response to intra-raphe infusion of corticotropin-releasing factor (100. ng) was measured 24. h after the last treatment in urethane-anesthetized (1.8. mg/kg, i.p.) rats using in vivo microdialysis. Rats pretreated with amphetamine showed significantly enhanced serotonin release in the central nucleus of the amygdala in response to corticotropin-releasing factor infusion when compared to saline pretreated rats. Furthermore, this enhanced response was blocked by the corticotropin-releasing factor type-2 receptor antagonist antisauvagine-30 (2μg) infused into the dorsal raphe nucleus. These results suggest increased sensitivity to corticotropin-releasing factor as mediated by type-2 receptors following chronic amphetamine treatment, which may underlie dysphoric states observed during amphetamine withdrawal.",
keywords = "(Rat), CRF receptor, Central nucleus of the amygdala, Dorsal raphe nucleus, Microdialysis",
author = "Scholl, {Jamie L} and Vuong, {Shawn M.} and Forster, {Gina L}",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.ejphar.2010.07.008",
language = "English (US)",
volume = "644",
pages = "80--87",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala

AU - Scholl, Jamie L

AU - Vuong, Shawn M.

AU - Forster, Gina L

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Amphetamine use is associated with dysphoric states, including heightened anxiety, that emerge within 24. h of withdrawal from the drug. Corticotropin-releasing factor increases serotonin release in the central nucleus of the amygdala, and this neurochemical circuitry may play a role in mediating fear and anxiety states. We have previously shown that chronic amphetamine treatment increases corticotropin-releasing factor receptor type-2 levels in the serotonergic dorsal raphe nucleus of the rat. Therefore, we hypothesized that chronic amphetamine treatment would enhance the amygdalar serotonergic response to corticotropin-releasing factor infused into the dorsal raphe nucleus. Male rats were injected once-daily with d-amphetamine (2.5. mg/kg i.p., or saline) for two weeks. Serotonin release within the central nucleus of the amygdala in response to intra-raphe infusion of corticotropin-releasing factor (100. ng) was measured 24. h after the last treatment in urethane-anesthetized (1.8. mg/kg, i.p.) rats using in vivo microdialysis. Rats pretreated with amphetamine showed significantly enhanced serotonin release in the central nucleus of the amygdala in response to corticotropin-releasing factor infusion when compared to saline pretreated rats. Furthermore, this enhanced response was blocked by the corticotropin-releasing factor type-2 receptor antagonist antisauvagine-30 (2μg) infused into the dorsal raphe nucleus. These results suggest increased sensitivity to corticotropin-releasing factor as mediated by type-2 receptors following chronic amphetamine treatment, which may underlie dysphoric states observed during amphetamine withdrawal.

AB - Amphetamine use is associated with dysphoric states, including heightened anxiety, that emerge within 24. h of withdrawal from the drug. Corticotropin-releasing factor increases serotonin release in the central nucleus of the amygdala, and this neurochemical circuitry may play a role in mediating fear and anxiety states. We have previously shown that chronic amphetamine treatment increases corticotropin-releasing factor receptor type-2 levels in the serotonergic dorsal raphe nucleus of the rat. Therefore, we hypothesized that chronic amphetamine treatment would enhance the amygdalar serotonergic response to corticotropin-releasing factor infused into the dorsal raphe nucleus. Male rats were injected once-daily with d-amphetamine (2.5. mg/kg i.p., or saline) for two weeks. Serotonin release within the central nucleus of the amygdala in response to intra-raphe infusion of corticotropin-releasing factor (100. ng) was measured 24. h after the last treatment in urethane-anesthetized (1.8. mg/kg, i.p.) rats using in vivo microdialysis. Rats pretreated with amphetamine showed significantly enhanced serotonin release in the central nucleus of the amygdala in response to corticotropin-releasing factor infusion when compared to saline pretreated rats. Furthermore, this enhanced response was blocked by the corticotropin-releasing factor type-2 receptor antagonist antisauvagine-30 (2μg) infused into the dorsal raphe nucleus. These results suggest increased sensitivity to corticotropin-releasing factor as mediated by type-2 receptors following chronic amphetamine treatment, which may underlie dysphoric states observed during amphetamine withdrawal.

KW - (Rat)

KW - CRF receptor

KW - Central nucleus of the amygdala

KW - Dorsal raphe nucleus

KW - Microdialysis

UR - http://www.scopus.com/inward/record.url?scp=77955773086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955773086&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2010.07.008

DO - 10.1016/j.ejphar.2010.07.008

M3 - Article

VL - 644

SP - 80

EP - 87

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -